Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 billion in sales, driven by new drug launches.

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Tirzepatide, the active ingredient in Eli Lilly's diabetes drug Mounjaro, may be an effective ... subcutaneous fat in these patients makes "each injection painful," according to Svetlana Ten ...

This is an enormous opportunity, and Lilly's clinical pipeline looks well positioned. Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now ...

Around 180,000 people with type 2 diabetes in the UK could be in line for treatment with Eli Lilly's Mounjaro after the ... Novo Nordisk – both given by injection once a week – as well as ...

Similar to third-quarter 2024, management stated that sales of both Mounjaro and Zepbound were hurt by lower-than-expected channel inventory of the products. Eli Lilly is scheduled to report ...

Imagine this: You walk into your doctor and get your yearly flu vaccine and a yearly dose of your weight-loss injection. If Eli Lilly has its ... "weight-loss" shots: Mounjaro, prescribed for ...

FILE PHOTO: An injection pen of Zepbound, Eli Lilly’s ... of upcoming catalysts." Lilly expects its most-watched blockbuster products — GLP-1 tirzepatide products Mounjaro and Zepbound ...